Chester County News and Community Website
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has unveiled its new branded television commercial, “Steve’s Journey,” as part of a broader effort to educate the public about Dupuytren’s contracture, a progressive …
Endo, Inc. Launches New “Steve’s Journey” Campaign to Raise Awareness About Dupuytren’s Contracture Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has launched its new television commercial and disease awareness campaign, “I Got Somebody,” to encourage men experiencing symptoms of Peyronie’s disease (PD) to take …
Endo, Inc. Launches “I Got Somebody” Campaign to Raise Awareness About Peyronie’s Disease Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has introduced a new tool to support men dealing with Peyronie’s disease (PD). The self-assessment screening app, designed to help individuals identify and …
ICYMI: New App Helps Men Address Peyronie’s Disease Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has introduced a free self-assessment app designed to help men manage Peyronie’s disease (PD), a condition involving penile curvature that can be both …
New App Aims to Empower Men with Peyronie’s Disease Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has announced the start of shipments for its doxycycline for injection, USP 100 mg/vial, a generic alternative to DOXY 100™. This marks a significant …
Endo Inc. Launches Generic Doxycycline for Injection Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has secured U.S. Food and Drug Administration (FDA) approval for the commercial production of VASOSTRICT® (vasopressin injection, USP) at its newly constructed aseptic manufacturing …
Endo Receives FDA Approval for New Sterile Injectable Facility in India Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has introduced the ADRENALIN® ready-to-use premixed intravenous (IV) bag, the first FDA-approved epinephrine premixed bag prepared directly by the manufacturer. This significant development is …
Endo, Inc. Launches FDA-Approved ADRENALIN® Premixed Epinephrine Bag Read More
MALVERN, PA – Endo, Inc. (OTCQX: NDOI) has expanded its voluntary recall of certain Clonazepam Orally Disintegrating Tablets, USP (C-IV) due to potential mislabeling on product cartons. The affected lots, …
Endo Expands Recall of Clonazepam Tablets Due to Mislabeling Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has reached a definitive agreement with MC2 Therapeutics to commercialize Wynzora® Cream in Canada through its subsidiary, Paladin Pharma Inc. This strategic move …
Endo, Inc. Partners with MC2 Therapeutics to Bring Wynzora® Cream to Canadian Market Read More MALVERN, PA — Endo, Inc. (OTCQX: NDOI) announced its financial results for the third quarter ending September 30, 2024, following the acquisition of assets from Endo International plc earlier this …
Endo, Inc. Reports Third-Quarter 2024 Financial Results Amid Strategic Developments Read More